Skip to Content

BriaCell Therapeutics Corp - Stock Quote BCTX

Rating as of

Morningstar's BriaCell Therapeutics Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

BriaCell Therapeutics Corp's Company Profile

Business Description

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

Contact
235 - 15th Street, Suite 300, West Vancouver
Vancouver, BC, V7T 2X1, Canada
T +1 604 921-1810
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jan 31, 2022
Fiscal Year End Jul 31, 2022
Stock Type
Employees 6